While currently available T2DM treatments, including oral anti-diabetic drugs and insulin subcutaneous injection, can alleviate hyperglycaemia or temporarily improve insulin sensitivity in target tissues, these can neither reverse insulin resistance nor the progressive β-cell dysfunction; that is, none of these therapies modulate the course of the disease [6]. Here, INS is linked to Hyperglycemia.